Dr. Hans Iding (Senior Principal Scientist)
F. Hoffmann-La Roche Ltd
Synthetic Molecules Technical Development
Process Chemistry & Catalysis
Associated partner /
Co-definition of research and market needs,
Co-supervision of research project
Hans Iding applies biocatalysis as a Senior Principal Scientist at Hoffmann-La Roche Basel and is responsible for enzymatic transformations to support the drug development chain from Discovery up to Development delivering chiral intermediates as well as commercial processes.
Hans graduated at the chemistry department of the RWTH Aachen University, Germany. In the research center in Jülich, Germany at the Institute of Enzyme Technology he worked on the formate dehydrogenase (NADH regeneration) and the benzoyl formate decarboxylase (ThDP dependent carboligation) receiving his PhD. Subsequently in a post-doctoral position at Hoffmann-La Roche Basel he implemented an automated enzyme screening. Since 2000, Hans is heading a biotransformation laboratory. He has additionally taken over the responsibility as a chemical project leader within his department – Process Chemistry & Catalysis and was ad interim leading the biocatalysis group. His scientific contributions are described in 41 publications and 25 patents.
Applied enzyme catalysis form screening to ton scale,
co-designing new synthesis routes, process transfer, enzyme control strategy, enzyme evolution, investigation of new enzyme classes, extending enzyme libraries, …
The later points are quite often achieved in collaborations!
Throughout our 125-year history, Roche has grown into one of the world’s largest biotech companies, as well as a leading provider of in-vitro diagnostics and a global supplier of transformative innovative solutions across major disease areas. Our commitment to our people, partners, stakeholders and, most importantly, our patients remains as strong as it was on the first day of our journey.
Behind every presentation of each product sold by Roche is the involvement of Pharma Global Technical Operations (PT). Starting with Phase I of the development process and continuing through to product maturity, PT makes medicines at sites around the world and includes more than 12 000 employees worldwide.
“Global Technical Development” (PTD) is an organization of over two thousand people globally that are integral for the mission of Roche to develop meaningful medicines for patients. Therefore, PTD actively collaborates and develops innovative technical solutions to bridge early-stage, late-stage and commercial product needs. The mandate of our organization is, to reliably deliver the pipeline and supply quality products to patients. Our organization excels in our work through innovation, collaboration, dedication, and mutual respect and adds value every day, continuously improving what we do.
“Synthetic Molecules Technical Development” (PTDC) brings a broad range of experience across drug substance (DS), drug product (DP), and collaborates closely with key partners in Research and Early Development, commercial manufacturing and Regulatory. PTDC drives late stage technical development of our synthetic molecules pipeline and manufacture of drug substance and drug product for clinical studies across our small molecules manufacturing network.
In the department “Process Chemistry & Catalysis”, we perform end-to-end process chemistry, from the design of new synthetic routes to the development of safe, reliable and sustainable commercial manufacturing processes of synthetic drug substances throughout all clinical phases until transfer to commercial manufacturing.
1. Stereoselective Synthesis of the IDO Inhibitor Navoximod F. St-Jean, R. Angelaud, S. Bachmann, D. E. Carrera, T. Remarchuk, K. A. Piechowicz, K. Niedermann, H. Iding, R. Meier, H. Hou, L. E. Sirois, J. Xu, M. Olbrich, P. Rege, M. Guillemot-Plass, F. Gosselin J. Org. Chem. 87, 7, 4955–4960, 2022. https://doi.org/10.1021/acs.joc.1c02994
2. Development of the Commercial Manufacturing Process for Ipatasertib S. Bachmann, H. Iding, C. Lautz, I. Thomé-Pfeiffer, C. Maierhofer, R. Mondière, P. Schmidt, C. Strasser, T. Bär, A. Aebi, A. Schuster, Chimia 2021, 75, 605, DOI: 10.2533/chimia.2021.605.
3. Identification of (S)-selective transaminases for the asymmetric synthesis of bulky chiral amines. I. V. Pavlidis, M. S. Weiß, M. Genz, P. Spurr, S. P. Hanlon, B. Wirz, H. Iding, U. T. Bornscheuer Nature Chemistry 8, 1076–1082 2016.